Related references
Note: Only part of the references are listed.Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis
Thomas Gremmel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Comparative lipidomics and proteomics analysis of platelet lipid rafts using different detergents
Vahideh Rabani et al.
PLATELETS (2016)
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information
Silvia Paoletta et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2015)
Heterodimerization With the Prostacyclin Receptor Triggers Thromboxane Receptor Relocation to Lipid Rafts
Salam Ibrahim et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties
Nicola Ferri et al.
DRUGS (2013)
Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications
Christopher N. Floyd et al.
CLINICAL PHARMACOKINETICS (2012)
Interaction of purinergic receptors with GPCRs, ion channels, tyrosine kinase and steroid hormone receptors orchestrates cell function
Paola Scodelaro Bilbao et al.
PURINERGIC SIGNALLING (2012)
Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel
Victor L. Serebruany
THROMBOSIS AND HAEMOSTASIS (2012)
Anti-platelet therapy: ADP receptor antagonists
Yanushi Dullewe Wijeyeratne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Proposed Serum Cholesterol Reference Measurement Procedure by Gas Chromatography-Isotope Dilution Mass Spectrometry
Selvin H. Edwards et al.
CLINICAL CHEMISTRY (2011)
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James et al.
AMERICAN HEART JOURNAL (2009)
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Lars Wallentin
EUROPEAN HEART JOURNAL (2009)
Trafficking of the microdomain scaffolding protein reggie-1/flotillin-2
Matthias F. Langhorst et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2008)
P2Y1 Receptor Activation Elicits Its Partition out of Membrane Rafts and Its Rapid Internalization from Human Blood Vessels: Implications for Receptor Signaling
Andres Norambuena et al.
MOLECULAR PHARMACOLOGY (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts
Pierre Savi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The phospholipid composition and cholesterol content of platelet-derived microparticles:: a comparison with platelet membrane fractions
E Biró et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation
I del Conde et al.
BLOOD (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets
AR Hardy et al.
BLOOD (2004)
Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells
L Rajendran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The lipid raft microdomain-associated protein reggie-1/flotillin-2 is expressed in human B cells and localized at the plasma membrane and centrosome in PBMCs
S Solomon et al.
IMMUNOBIOLOGY (2002)
Share Paper
